Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns

11 Jul 2011
News

Sue Sutter @PinkSheetSutter sue.sutter@informa.com

Executive Summary

Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS053573

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS053573

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns

News

Executive Summary

Related Content

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert